Future of oncologic photodynamic therapy.
Photodynamic therapy (PDT) is a tumor-ablative and function-sparing oncologic intervention. The relative simplicity of photosensitizer application followed by light activation resulting in the cytotoxic and vasculartoxic photodynamic reaction has allowed PDT to reach a worldwide audience. With several commercially available photosensitizing agents now on the market, numerous well designed clinical trials have demonstrated the efficacy of PDT on various cutaneous and deep tissue tumors. However, current photosensitizers and light sources still have a number of limitations. Future PDT will build on those findings to allow development and refinement of more optimal therapeutic agents and illumination devices. This article reviews the current state of the art and limitations of PDT, and highlight the progress being made towards the future of oncologic PDT.
Allison
Ron R
RR
21st Century Oncology, 801 WH Smith Blvd, Greenville, NC 27834, USA. rallison@rtsx.com
Bagnato
Vanderlei S
VS
Sibata
Claudio H
CH
D000622:Aminolevulinic Acid / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D017323:Dihematoporphyrin Ether / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D008652:Mesoporphyrins / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use; D053758:Nanoparticles; D009369:Neoplasms / Q000188:drug therapy*; D010100:Oxygen / Q000378:metabolism; D010778:Photochemotherapy / Q000295:instrumentation / Q000379:methods / Q000639:trends*; D017319:Photosensitizing Agents / Q000494:pharmacology / Q000528:radiation effects / Q000627:therapeutic use
D008652:Mesoporphyrins; D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid; D017323:Dihematoporphyrin Ether; C072269:temoporfin; D010100:Oxygen